Ritonavir/saquinavir safety concerns curtail antiretroviral therapy options for tuberculosis–HIV-co-infected patients in resource-constrained settings.

Gray, Andrew Lofts.Abdool Karim, Salim Safurdeen.Gengiah, Tanuja Narayansamy.2013-05-072013-05-0720052005Gray, A.L., Abdool Karim, S.S. & Gengiah, T.N. 2006. Ritonavir/saquinavir safety concerns curtail antiretroviral therapy options for tuberculosis–HIV-co-infected patients in resource-constrained settings. AIDS 20(2) pp. 302-303.0269-9370http://hdl.handle.net/10413/8835CorrespondenceNo abstract available.enHighly active antiretroviral treatment.HIV infections--Treatment.Tuberculosis--Treatment.Antiretroviral therapy.Ritonavir/saquinavir.Tuberculosis-HIV co-infected patients.Co-infection.HAART.Ritonavir/saquinavir safety concerns curtail antiretroviral therapy options for tuberculosis–HIV-co-infected patients in resource-constrained settings.Other